Jessica Sachs, M.D., serves as the Chief Medical Officer at COGENT BIOSCIENCES INC, a biopharmaceutical company focused on developing novel cancer therapies. Dr. Sachs brings a wealth of experience in oncology and drug development to her role, having spent over a decade in the biopharmaceutical industry. Prior to joining Cogent, she held key positions at leading companies such as Novartis and Tesaro, where she was instrumental in advancing several oncology programs from early-stage development through to regulatory approval and commercialization. At Novartis, Dr. Sachs played a pivotal role in the development of multiple cancer therapies, including the groundbreaking drug ribociclib, which has become a standard of care for patients with HR+/HER2- advanced breast cancer. Her strategic leadership and deep understanding of clinical development were critical in navigating the complex landscape of oncology drug development. Before her industry career, Dr. Sachs completed her medical training and residency in internal medicine at the University of Pennsylvania, followed by a fellowship in hematology and oncology at the Dana-Farber Cancer Institute and Harvard Medical School. As Chief Medical Officer at Cogent Biosciences, Dr. Sachs is responsible for overseeing the company's clinical development strategy and execution. Her role involves leading the advancement of Cogent's pipeline of targeted therapies, with a focus on precision medicine approaches to treat various types of cancer. Under her leadership, Cogent is working to bring innovative treatments to patients, leveraging Dr. Sachs' extensive experience and commitment to improving cancer care. Her contributions are vital to the company's mission of transforming the treatment landscape for cancer patients worldwide.